Literature DB >> 17879294

Enhanced oral bioavailability of doxorubicin in a dendrimer drug delivery system.

Weilun Ke1, Yansong Zhao, Rongqin Huang, Chen Jiang, Yuanying Pei.   

Abstract

PAMAM dendrimers can permeate across intestinal epithelial barriers suggesting their potential as oral drug carriers. In the present study, we have developed a drug-PAMAM complex for oral administration. The loading of a model drug, doxorubicin into PAMAM, the cellular uptake and pharmacokinetics of the doxorubicin-PAMAM complex were studied. As the results, the cellular uptake of doxorubicin in Caco-2 cells treated with the doxorubicin-PAMAM complex was increased significantly with an increase in concentration and time, as compared to that treated with free doxorubicin. And the transport efficiency of the doxorubicin-PAMAM complex from the mucosal side to the serosal side was 4-7 times higher than that of free doxorubicin in different segments of small intestines of rat. The doxorubicin-PAMAM complex led to the bioavailability that was more than 200-fold higher than that of free doxorubicin after oral administration. These results indicate that PAMAM dendrimer is a promising novel carrier to enhance the oral bioavailability of drug, especially for the P-glycoprotein (P-gp) substrates. 2007 Wiley-Liss, Inc

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 17879294     DOI: 10.1002/jps.21155

Source DB:  PubMed          Journal:  J Pharm Sci        ISSN: 0022-3549            Impact factor:   3.534


  24 in total

1.  Cellular entry of G3.5 poly (amido amine) dendrimers by clathrin- and dynamin-dependent endocytosis promotes tight junctional opening in intestinal epithelia.

Authors:  Deborah S Goldberg; Hamidreza Ghandehari; Peter W Swaan
Journal:  Pharm Res       Date:  2010-04-22       Impact factor: 4.200

Review 2.  Designing dendrimers for drug delivery and imaging: pharmacokinetic considerations.

Authors:  Wassana Wijagkanalan; Shigeru Kawakami; Mitsuru Hashida
Journal:  Pharm Res       Date:  2010-12-23       Impact factor: 4.200

Review 3.  Poly(amido amine) dendrimers in oral delivery.

Authors:  Venkata K Yellepeddi; Hamidreza Ghandehari
Journal:  Tissue Barriers       Date:  2016-04-06

Review 4.  Transepithelial transport and toxicity of PAMAM dendrimers: implications for oral drug delivery.

Authors:  S Sadekar; H Ghandehari
Journal:  Adv Drug Deliv Rev       Date:  2011-09-29       Impact factor: 15.470

5.  Oral absorption enhancement of probucol by PEGylated G5 PAMAM dendrimer modified nanoliposomes.

Authors:  Qian Ma; Yingchun Han; Cong Chen; Yini Cao; Siling Wang; Wenwen Shen; Huayu Zhang; Yanzhi Li; Mallory A van Dongen; Bing He; Maomao Yu; Lu Xu; Mark M Banaszak Holl; George Liu; Qiang Zhang; Rong Qi
Journal:  Mol Pharm       Date:  2015-01-27       Impact factor: 4.939

6.  In Vitro and In Vivo Co-delivery of siRNA and Doxorubicin by Folate-PEG-Appended Dendrimer/Glucuronylglucosyl-β-Cyclodextrin Conjugate.

Authors:  Ahmed Fouad Abdelwahab Mohammed; Taishi Higashi; Keiichi Motoyama; Ayumu Ohyama; Risako Onodera; Khaled Ali Khaled; Hatem Abdelmonsef Sarhan; Amal Kamal Hussein; Hidetoshi Arima
Journal:  AAPS J       Date:  2019-04-16       Impact factor: 4.009

7.  pH-responsive hydrogels with dispersed hydrophobic nanoparticles for the oral delivery of chemotherapeutics.

Authors:  Cody A Schoener; Heather N Hutson; Nicholas A Peppas
Journal:  J Biomed Mater Res A       Date:  2012-12-28       Impact factor: 4.396

8.  PEGylated PAMAM dendrimer-doxorubicin conjugates: in vitro evaluation and in vivo tumor accumulation.

Authors:  Saijie Zhu; Minghuang Hong; Lihong Zhang; Guotao Tang; Yanyan Jiang; Yuanying Pei
Journal:  Pharm Res       Date:  2009-10-28       Impact factor: 4.200

9.  Transepithelial transport of PEGylated anionic poly(amidoamine) dendrimers: implications for oral drug delivery.

Authors:  Deborah M Sweet; Rohit B Kolhatkar; Abhijit Ray; Peter Swaan; Hamidreza Ghandehari
Journal:  J Control Release       Date:  2009-04-22       Impact factor: 9.776

10.  Poly(amido amine) dendrimers as absorption enhancers for oral delivery of camptothecin.

Authors:  S Sadekar; G Thiagarajan; K Bartlett; D Hubbard; A Ray; L D McGill; H Ghandehari
Journal:  Int J Pharm       Date:  2013-08-08       Impact factor: 5.875

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.